logo
Weight loss implants to increase compliance and cut admin burden for patients

Weight loss implants to increase compliance and cut admin burden for patients

Yahoo03-04-2025

Obesity is a chronic metabolic disease characterised by excess body weight and comorbidities that can become life-threatening. The obesity treatment landscape has immensely improved in the past few years, but compliance remains a problem for patients. According to GlobalData, the next generation of obesity therapies will see candidates improving patients' experience, from higher tolerability profiles to lower dosage frequency and better routes of administration.
Vivani Medical, an emerging biopharmaceutical company in the metabolic diseases space, is developing subdermal implants that are changed once or twice per year, delivering GLP-1R agonist with no need for a weekly injection.
Thanks to their NanoPortal implant technology, NPM-115 and NPM-139 will soon be able to deliver exenatide and semaglutide respectively in patients with obesity. The company has recently completed enrolment for its first-in-human trial, LIBERATE-1, investigating NPM-115. A trial of NPM-139 is expected to follow in due course.
In late March 2025, results from NPM-139's preclinical study were announced. It confirmed that the treatment resulted in close-to-20% placebo-adjusted weight loss from a single administration and that this semaglutide implant could be eligible for once-yearly administration.
Key opinion leaders (KOLs) interviewed by GlobalData have stated that a twice-yearly or once-yearly therapy administration would be a great improvement from the current once-weekly administration. While a once-monthly injection is not seen as a major difference, experts seem enthusiastic about longer interval options. The self-administering nature of injection pens is not ideal, according to KOLs, as dosing errors can occur and patients can forget about them. Instead, a once or twice-yearly injection could be performed by a doctor or in a hospital setting, reducing patient responsibility and risk of error.
The application of the implant will likely be different to a small subcutaneous injection, so patients' perspectives on the implant administration experience will be crucial for treatment uptake and the perception of these candidates. Reduced frequency of administration is very encouraging for patient compliance, and if the implant delivery is smooth and safe, it could secure a large number of patients who are adverse to weekly injections and self-administration. This is especially beneficial as they are likely to need lifelong treatment.
"Weight loss implants to increase compliance and cut admin burden for patients" was originally created and published by Pharmaceutical Technology, a GlobalData owned brand.
The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site.

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Nika Pharmaceuticals, Inc. to Present at the Life Sciences Virtual Investor Forum June 11th-12th
Nika Pharmaceuticals, Inc. to Present at the Life Sciences Virtual Investor Forum June 11th-12th

Yahoo

time37 minutes ago

  • Yahoo

Nika Pharmaceuticals, Inc. to Present at the Life Sciences Virtual Investor Forum June 11th-12th

Company invites individual and institutional investors, as well as advisors and analysts, to attend online at HENDERSON, Nev., June 10, 2025 (GLOBE NEWSWIRE) -- Nika Pharmaceuticals, Inc. (OTCQB:NIKA), based in Colorado, focused on cures for life-threatening diseases, today announced that Dimitar Savov, CEO, will present live at the Life Sciences Virtual Investor Frum hosted by on June 11th, 2025 DATE: June 11th TIME: 1:00 PM ETLINK: REGISTER HEREAvailable for 1x1 meetings: June 12th-17th between 09:00am ET and 11:30am ET This will be a live, interactive online event where investors are invited to ask the company questions in real-time. If attendees are not able to join the event live on the day of the conference, an archived webcast will also be made available after the event. It is recommended that online investors pre-register and run the online system check to expedite participation and receive event updates. Learn more about the event at Recent Company Highlights On May 19, 2025, NIKA published a market analysis for the countries of Ukraine, Syria, Jordan, Iraq, UAE, where NIKA has exclusive distribution agreements and has estimated a total of around €656 million in potential revenue. NIKA's partner company, Nika Europe, has made the second $195,554 payment for the vial production line and is currently finalizing the details of the clean rooms design in order to start construction. The production facility is expected to be completed in H2, 2025. On April 11, 2025, Nika Pharmaceuticals, Inc. published a report on the therapeutic effect and potential economic impact of ITV-1, which can be found here. On July 11, 2024 Nika Pharmaceuticals, Inc. signed an exclusive distribution agreement for the Republic of Nigeria. Under the terms, NIKA will receive €1,980 per each set of ITV-1 with two sets necessary for each treatment, which could result in €7.9 billion revenue. About Nika Pharmaceuticals, Inc. Nika Pharmaceuticals, Inc. (NIKA) is a pharmaceutical company, specializing in the treatment of HIV/AIDS, Hepatitis B and C, Rheumatoid Arthritis, Cancer, Diabetes, and all diseases, for which strengthened cell immunity is of vital importance. NIKA's intellectual property includes six drugs in injection form – two of which have successfully undergone clinical trials with good treatment results – four drugs in tablet form, and eleven dietary supplements. NIKA's goal is to not only achieve corporate profits, but to provide better and easier access to life-saving medicinal drugs and useful dietary supplements. Find more on Forward-looking Statement: This press release contains forward-looking statements. Certain statements, other than purely historical information, including estimates, projections, statements relating to our business plans, objectives, and expected operating results, and the assumptions upon which those statements are based, are 'forward- looking statements.' These forward-looking statements generally are identified by the words 'believes,' 'expects,' 'anticipates,'' estimates,' 'intends,' 'strategy,' 'plan,' 'may,' 'will,' 'would,' 'will be,' 'will continue,' 'will likely result,' and similar expressions. Forward-looking statements are based on current expectations and assumptions that are subject to risks and uncertainties which may cause actual results to differ materially from the forward-looking statements. Our ability to predict results or the actual effect of future plans or strategies is inherently uncertain. About Virtual Investor Conferences®Virtual Investor Conferences (VIC) is the leading proprietary investor conference series that provides an interactive forum for publicly traded companies to seamlessly present directly to investors. Providing a real-time investor engagement solution, VIC is specifically designed to offer companies more efficient investor access. Replicating the components of an on-site investor conference, VIC offers companies enhanced capabilities to connect with investors, schedule targeted one-on-one meetings and enhance their presentations with dynamic video content. Accelerating the next level of investor engagement, Virtual Investor Conferences delivers leading investor communications to a global network of retail and institutional investors. CONTACTS:Nika Pharmaceuticals, Clifford P. RedekopTitle Corporate SecretaryPhone (702) 326-3615 Email cliffredekop@ Virtual Investor Conferences John M. ViglottiSVP Corporate Services, Investor AccessOTC Markets Group (212) 220-2221johnv@ in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Doctors warn about ‘very real risks' of Ozempic ‘golden dosing' trend: ‘Recipes for disaster'
Doctors warn about ‘very real risks' of Ozempic ‘golden dosing' trend: ‘Recipes for disaster'

New York Post

time44 minutes ago

  • New York Post

Doctors warn about ‘very real risks' of Ozempic ‘golden dosing' trend: ‘Recipes for disaster'

GLP-1 users might be jabbing for weight loss, but many are trying to combat cash loss by squeezing an extra dose out of their medication. The trend, dubbed 'golden dosing,' has been hyped by social media users as a way to get more bang for your buck. But doctors are warning it could be dangerous — and even set back your weight loss goals. 'Using a medication outside of its prescribed method is always risky — and in this case, especially unnecessary,' Dr. Michael Snyder, medical director of Bariatric Surgery at Rose Medical Center and an in-house expert at FuturHealth, told The Post. Advertisement 4 Surveys show that roughly 1 in 8 US adults have tried GLP-1 drugs. millaf – What is golden dosing? GLP-1 drugs like Ozempic, Mounjaro and Wegovy come in injectable pens that contain four doses, with each device lasting about a month. But some users have noticed that their pens often have leftover liquid after their final jab. This extra medication isn't a mistake. It's designed to allow for an initial flow check and to ensure that each of the four doses is accurate and complete. Advertisement Nevertheless, some TikTok users are extracting this leftover liquid with syringes and needles, using it as a fifth and final 'golden dose.' With out of pockets costs for these drugs sometimes topping $1,000 a pen, pulling out the extra medication has become a way to cut back a bit on exorbitant costs. But experts say the trend raises some major red flags. 'The 'golden dose' is more of a cost-saving strategy than one focused on safety and effectiveness,' Dr. Shiara Melissa Ortiz-Pujols, a bariatric surgeon at Northwell Health, told The Post. Advertisement 4 Typically, GLP-1 pens contain four doses. Fernanda – A dose of confusion GLP-1 pens deliver pre-measured doses that are carefully prescribed by healthcare providers based on factors like weight and health status. 'Any deviation — even what might seem like a 'small' one — can disrupt how your body responds,' Snyder warned. Advertisement GLP-1s are typically titrated, meaning the dosage is gradually increased over time to help the body adjust to the drug. 'As we increase the dose, we expect greater effectiveness, but we also face a higher risk of severe side effects,' Ortiz-Pujols explained. 4 Taking too much of the medication can lead to painful gastrointestinal effects. – Increasing your dose too quickly or taking inconsistent amounts week to week can worsen side effects, she said. It could also complicate your treatment plan, making it difficult for doctors to accurately track how your body is responding to the medications and make informed adjustments based on your personal needs, Snyder cautioned. From hack to hazard Attempting to recover leftover medication using a syringe also carries 'very real risks' for your health, Snyder said. Even minor miscalculations can lead to overdoses, triggering symptoms like nausea, vomiting and even pancreatitis. Advertisement 4 There's a major risk for bacterial growth if the syringe isn't completely sterile. Jo Panuwat D – On the flip side, underdosing can blunt the drug's effectiveness, resulting in weight regain and glucose instability. 'To put it simply, how comfortable would you feel using what you think is the 'right amount' of a blood pressure medication, a blood thinner, or a narcotic?' Snyder posed. 'All of those could be recipes for disaster. This situation is no different.' A hidden danger Advertisement The trend also poses a serious risk of infection. 'GLP-1 pens are designed to be used as a sealed system,' Snyder said. 'Using an external syringe breaks sterility, exposing the medication to bacteria during handling — even from clean-looking surfaces or hands.' This can lead to local infections at the injection site or even systemic infections, Snyder noted, emphasizing that the risk is particularly high for those who reuse syringes or directly touch the drug solution. 'There's no reliable way to make this DIY method safe,' Snyder said. 'That's why these pens are single-use and designed for highly controlled administration.'

PSG Releases 2025 Drug Benefit Design Report: PBM Unbundling Gains Momentum and Payers Navigate GLP-1 Coverage Decisions Amid Rising Costs
PSG Releases 2025 Drug Benefit Design Report: PBM Unbundling Gains Momentum and Payers Navigate GLP-1 Coverage Decisions Amid Rising Costs

Yahoo

time2 hours ago

  • Yahoo

PSG Releases 2025 Drug Benefit Design Report: PBM Unbundling Gains Momentum and Payers Navigate GLP-1 Coverage Decisions Amid Rising Costs

New Research Reveals Strategic Approaches to Balancing Member Access and Affordability with Pharmacy Spend Control DALLAS, June 10, 2025--(BUSINESS WIRE)--Pharmaceutical Strategies Group ("PSG"), an EPIC company, published its 2025 Trends in Drug Benefit Design Report, delivering critical insights into how payers are navigating a rapidly evolving pharmacy benefits landscape. For three decades, this industry report has been an essential resource for employers, health plans, and other stakeholders seeking to understand and adapt to changes in pharmacy benefit design and management. The 2025 edition addresses both foundational benefit design elements — including formulary and network design, utilization management, and cost sharing — and today's most pressing challenges, such as GLP-1 coverage decisions, heightened fiduciary liability concerns, and the accelerating shift toward unbundled PBM arrangements. Drawing from extensive research and insights from benefits leaders nationwide, the report provides actionable intelligence for organizations working to balance member access and affordability with effective pharmacy spend control. Read all the insights in the full report available here. Navigating the GLP-1 Surge While nearly all plans cover GLP-1s for type 2 diabetes (92%), only 39% currently cover GLP-1s for obesity. Cost is a large concern for payers with respect to GLP-1s for obesity, but even so, the survey finds that nearly half of plans that currently exclude these drugs from coverage say they would not cover the drugs at any price. Benefits leaders must balance the overwhelming demand for these medications with their cost as well as the decision to cover a treatment for obesity. "GLP-1s are the area of this report where we see the most variation in perception and strategy," said Morgan Lee, Senior Director of Research & Strategy at PSG. "Respondents are very concerned about GLP-1 affordability for the plan, and many are concerned about off-label use of GLP-1s for type 2 diabetes, yet nearly half don't know how much of their current spending is for off-label purposes. We're also seeing continued variation in how plans perceive GLP-1s for obesity, whether as lifestyle drugs or as treatments for a chronic disease. As the GLP-1 landscape rapidly evolves with expanded indications, direct-to-consumer offerings, and more, payers will continue to have new considerations and decisions to navigate." Unbundling Pharmacy Benefit Management One of the most disruptive strategies explored in the report is the shift toward unbundling PBM services. This year's report revealed that a growing number of payers are evaluating or already pursuing this modular approach, which allows organizations to separate functions, such as claims processing, formulary management, and rebate negotiation, and contract them independently. "We're seeing rising interest in partial or fully modular PBM arrangements," shared Beth Hebert-Silvia, Senior Vice President, Health Plans Practice Leader at PSG. "This strategy isn't plug-and-play. It requires sophisticated design and execution, but it enables plans to align each element of their pharmacy benefit with their unique needs. More importantly, it empowers them with greater transparency and control." Rethinking Cost Sharing in a Price-Sensitive Era Cost sharing remains the most visible and impactful element of pharmacy benefit design for members. According to the report, 70% of payers are contemplating changes to their cost sharing structures, with many exploring increases in copays, coinsurance, or deductibles. To help members manage their cost sharing, over half of payers promote cost-sharing transparency tools, although views are mixed on the effectiveness and value of these tools. Employers Grapple with Fiduciary Risk and Future Investment Many benefits leaders are concerned about exposure to fiduciary risk through pharmacy benefits and are taking steps to protect themselves. One in three employers report making moderate or large changes to their approach to fiduciary responsibility in light of recent lawsuits alleging mismanagement of pharmacy benefits. "Employers are more alert than ever to the legal and financial responsibilities tied to benefit partnerships and decisions," said Mike Medel, Senior Vice President and Practice Lead, Plan Sponsors at PSG. "We're seeing employers invest more time in vendor selection, pricing models, and governance processes because they know the risks of fiduciary criticism are real and growing." The report also reveals that half of employers expect to increase their investment in benefits over the next one to two years, with pharmacy benefits ranking among the top three targeted areas for expansion. Read all the insights in the full report available here. About the 2025 Trends in Drug Benefit Design Report The Trends in Drug Benefit Design Report provides in-depth insights into traditional (non-specialty) drug benefit trends and strategies and focuses on drug benefit design for the 2025 benefit year among employers, union/Taft-Hartley, and health plan respondents. The survey sample informing this report included 222 benefits leaders. Issues specific to specialty drugs are included in a separate report — Trends in Specialty Drug Benefits. This report, as well as prior annual reports conducted by PSG, can be found at About Pharmaceutical Strategies Group (PSG) Pharmaceutical Strategies Group, an EPIC company, relentlessly advocates for clients as they navigate complex and ever-changing drug cost management challenges. PSG is an independent consultant, empowering healthcare payers to manage their pharmacy program better. As a strategic partner, PSG helps clients by providing industry-leading intelligence and technologies to realize billions of dollars in drug cost savings for clients every year. View source version on Contacts Media Contact Gregory FCA for PSGEPIC@ Sign in to access your portfolio

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store